Tests brentuximab with PD-1 blockade for relapsed Hodgkin lymphoma
Tests brentuximab with PD-1 blockade, then stem cell transplant, in people with returned Hodgkin lymphoma.
Plain-language title generated from the registry record
Registry title: Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
Key facts
- Where
- León, MexicoSee the site
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 90 years old?
Source: NCT05595447, who can take part
Where in Mexico
- Hospital Regional Alta Especialidad BajioLeón, MexicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital Regional de Alta Especialidad del Bajio
- Trial code
- NCT05595447
- Record updated
- 12 March 2025
- Original description
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.Read full original descriptionShow less
Rescue With Brentuximab Plus PD-1 Blockade Followed by Autotransplantation and Consolidation With Brentuximab Plus PD-1 Blockade in Patients With Relapsed/Refractory Hodgkin Lymphoma: Exploratory Single-arm Analysis
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.
What is the progression-free survival and rate of metabolic responses complete in patients with high-risk R/R HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade
1?
Inclusion: Relapsed/refractory Hodgkin lymphoma to ABVD with definition of high risk; Age ≥ 18 years and ≤ 90 years; Adequate liver function, defined as:; Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN); Serum aspartate aminotransferase (AST) ≤ 3.0 x ULN; Serum alanine aminotransferase (ALT) ≤ 3.0 x ULN; Adequate renal functions, defined as:; Serum creatinine ≤ 1.5x ULN or glomerular filtration rate \> 50ml/min; ECOG performance status ≤ 3; Women of reproductive potential should have a serum pregnancy test or negative urine; Prior signature of the informed consent.
Exclusion: Voluntary withdrawal from the study; Develop grade 3 or 4 toxicity according to the INH scale; Loss of follow-up.